Pharming Affirms FY2026 Sales Guidance of $380.000M-$390.000M vs $383.333M Est
Benzinga Newsdesk 3 weeks ago
NewsGuidance
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Pharming (NASDAQ:PHAR) affirms FY2026 sales outlook from $380.000 million-$390.000 million to $380.000 million-$390.000 million vs $383.333 million estimate.
Pharming (NASDAQ:PHAR) affirms FY2026 sales outlook from $380.000 million-$390.000 million to $380.000 million-$390.000 million vs $383.333 million estimate.
